**Name of Journal:** *World Journal of Stem Cells*

**Manuscript NO:** 91879

**Manuscript Type:** LETTER TO THE EDITOR

**Reveal more mechanisms of precondition mesenchymal stem cells inhibiting inflammation**

Li Y *et al*. Pretreatment on MSCs

Yi Li, Qian-Qian Chen, En-Qiang Linghu

**Yi Li, Qian-Qian Chen,** Department of Gastroenterology, First Medical Center of Chinese PLA General Hospital, Beijing 100853, China

**En-Qiang Linghu,** Department of Gastroenterology and Hepatology, First Medical Center of Chinese PLA General Hospital, Beijing 100853, China

**Author contributions:** Li Y wrote the manuscript; Chen QQ and Linghu EQ revised the manuscript.

**Corresponding author: Qian-Qian Chen, MD, Associate Chief Physician, Associate Professor,** Department of Gastroenterology, First Medical Center of Chinese PLA General Hospital, No. 28 Fuxing Road, Haidian District, Beijing 100853, China. qian\_qian\_chen@163.com

**Received:** January 8, 2024

**Revised:** March 12, 2024

**Accepted:** March 27, 2024

**Published online:**

**Abstract**

Hypoxia can get more ability to inhibit inflammation. But how it impact on survival time of mesenchymal stem cells (MSCs) is confusing and how preconditioned MSCs inhibiting inflammation are partially known. Those issues decided the value of preconditioned MSCs by hypoxia.

**Key Words:** Mesenchymal stem cell; Hypoxia-inducible factor 1α; Hypoxia; Inflammation; Macrophage

Li Y, Chen QQ, Linghu EQ. Reveal more mechanisms of precondition mesenchymal stem cells inhibiting inflammation. *World J Stem Cells* 2024; In press

**Core Tip:** Precondition of mesenchymal stem cells (MSCs) can change the characteristic of MSCs and enhance its biological activity in specific aspects. Both hypoxia and the over-expression of hypoxia-inducible factor 1α can inhibit inflammation. But more mechanisms on precondition MSCs inhibiting inflammation should be revealed to promote curative effect.

**TO THE EDITOR**

Mesenchymal stem cells (MSCs) have immunomodulatory effects, which can effectively inhibit inflammation and promote tissue regeneration[1]. Its homing effect makes MSCs more targeted in regulating local inflammation. In order to enhance the immune regulatory ability of MSCs, researchers explored different methods to pretreated MSCs to improve the immune characteristics of MSCs[2,3]. The *World J Stem Cells* published a research paper titled “Hypoxia and inflammatory factor preconditioning enhances the immunosuppressive properties of human umbilical cord mesenchymal stem cells”[4], indicating that hypoxia culture and inflammatory factor pretreatment can enhance the ability of MSCs to inhibit inflammation. This paper confirmed through cell experiments that preconditioning MSCs have stronger anti-inflammatory abilities, but also observed the aging characteristics of MSCs, which means that the time for MSCs to exert active effects *in vivo* may be shortened.

**The value and the limitation of the article**

In fact, this study did not confirm at the animal level that preconditioning MSCs with hypoxia and inflammatory factors have a better inhibitory effect on inflammation. On the other hand, the aging characteristics of MSC need more evidence. The study from Haneef *et al*[5] indicated the proliferation, survival, and migration of MSCs are induced by hypoxic preconditioning. Anyhow, we have reason to assume that, just like the *in vitro* environment, the inflammatory and hypoxic environments in the body can also enhance the anti-inflammatory effect of MSCs.

**Revealing Mechanisms of Preconditioned MSCs is benefit to the Selection of treatment strategies**

However, does the survival time of MSCs *in vivo* affect their anti-inflammatory effects? The study by Yang *et al*[6] demonstrated at the animal level that preconditioned MSCs with hypoxia indeed have stronger anti-inflammatory regulatory effects than untreated MSCs. However, it is worth noting that this study only observed the effects of preconditioned MSCs at a single time point, lacking an evaluation based on the cumulative effects over a longer period of time. Therefore, currently we can only demonstrate that preconditioning MSCs is more effective in controlling acute inflammation, but it is difficult to say that the MSCs survive longer, the benefits are more obvious. Some studies have begun to challenge the view that “only live MSCs exert anti-inflammatory effects”. Schrodt *et al*[7] found heat-inactivated MSC induced human monocytes to distinct immunosuppressive phenotypes. Montalbán-Hernández *et al*[8] found fused cells between human-adipose-derived MSCs and monocytes keep stemness properties and acquire high mobility. Therefore, the next step should focus more on different ways to preconditioned MSCs and the anti-inflammatory mechanism of preconditioned MSCs. In addition, the hypoxia-inducible factor 1 alpha (HIF1α) signaling pathway can be activated by hypoxia and produce immune regulatory effects. Our team improved the immunosuppressive properties of MSCs by over-expressing HIF1α with genetic modification perspective[9]. This is another way to simulate preconditioned of hypoxia through genetic modification. Further evaluation can be conducted on the anti-inflammatory effects of MSCs with two different intervention methods: Hypoxia preconditioned and HIF1α overexpression.

**REFERENCES**

1 **Pratiwi DIN**, Alhajlah S, Alawadi A, Hjazi A, Alawsi T, Almalki SG, Alsalamy A, Kumar A. Mesenchymal stem cells and their extracellular vesicles as emerging therapeutic tools in the treatment of ischemic stroke. *Tissue Cell* 2024; **87**: 102320 [PMID: 38342071 DOI: 10.1016/j.tice.2024.102320]

2 **Najar M**, Bouhtit F, Rahmani S, Bouali A, Melki R, Najimi M, Lewalle P, Merimi M. The immunogenic profile and immunomodulatory function of mesenchymal stromal / stem cells in the presence of Ptychotis verticillata. *Heliyon* 2024; **10**: e24822 [PMID: 38317994 DOI: 10.1016/j.heliyon.2024.e24822]

3 **Hu C**, Li L. Preconditioning influences mesenchymal stem cell properties in vitro and in vivo. *J Cell Mol Med* 2018; **22**: 1428-1442 [PMID: 29392844 DOI: 10.1111/jcmm.13492]

4 **Li H**, Ji XQ, Zhang SM, Bi RH. Hypoxia and inflammatory factor preconditioning enhances the immunosuppressive properties of human umbilical cord mesenchymal stem cells. *World J Stem Cells* 2023; **15**: 999-1016 [PMID: 38058960 DOI: 10.4252/wjsc.v15.i11.999]

5 **Haneef K**, Salim A, Hashim Z, Ilyas A, Syed B, Ahmed A, Zarina S. Chemical Hypoxic Preconditioning Improves Survival and Proliferation of Mesenchymal Stem Cells. *Appl Biochem Biotechnol* 2023 [PMID: 37755639 DOI: 10.1007/s12010-023-04743-z]

6 **Yang Y**, Wu Y, Yang D, Neo SH, Kadir ND, Goh D, Tan JX, Denslin V, Lee EH, Yang Z. Secretive derived from hypoxia preconditioned mesenchymal stem cells promote cartilage regeneration and mitigate joint inflammation via extracellular vesicles. *Bioact Mater* 2023; **27**: 98-112 [PMID: 37006826 DOI: 10.1016/j.bioactmat.2023.03.017]

7 **Schrodt MV**, Behan-Bush RM, Liszewski JN, Humpal-Pash ME, Boland LK, Scroggins SM, Santillan DA, Ankrum JA. Efferocytosis of viable versus heat-inactivated MSC induces human monocytes to distinct immunosuppressive phenotypes. *Stem Cell Res Ther* 2023; **14**: 206 [PMID: 37592321 DOI: 10.1186/s13287-023-03443-z]

8 **Montalbán-Hernández K**, Casado-Sánchez C, Avendaño-Ortiz J, Casalvilla-Dueñas JC, Bonel-Pérez GC, Prado-Montero J, Valentín-Quiroga J, Lozano-Rodríguez R, Terrón-Arcos V, de la Bastida FR, Córdoba L, Laso-García F, Diekhorst L, Del Fresno C, López-Collazo E. Fused Cells between Human-Adipose-Derived Mesenchymal Stem Cells and Monocytes Keep Stemness Properties and Acquire High Mobility. *Int J Mol Sci* 2022; **23** [PMID: 36077075 DOI: 10.3390/ijms23179672]

9 **Zhu W**, Chen Q, Li Y, Wan J, Li J, Tang S. HIF-1α-Overexpressing Mesenchymal Stem Cells Attenuate Colitis by Regulating M1-like Macrophages Polarization toward M2-like Macrophages. *Biomedicines* 2023; **11** [PMID: 36979804 DOI: 10.3390/biomedicines11030825]

**Footnotes**

**Conflict-of-interest statement:** All the authors report no relevant conflicts of interest for this article.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

**Provenance and peer review:** Unsolicited article; Externally peer reviewed.

**Peer-review model:** Single blind

**Peer-review started:** January 8, 2024

**First decision:** March 9, 2024

**Article in press:**

**Specialty type:** Cell and tissue engineering

**Country/Territory of origin:** China

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): B

Grade C (Good): 0

Grade D (Fair): 0

Grade E (Poor): 0

**P-Reviewer:** Rotondo JC, Italy **S-Editor:** Wang JJ **L-Editor:** A **P-Editor:**